A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.
NCT ID: NCT00333112
Last Updated: 2014-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
398 participants
INTERVENTIONAL
2006-05-31
2007-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms
NCT00463541
Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder
NCT00454740
A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)
NCT00454896
Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life
NCT00573508
VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate
NCT01777217
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
solifenacin succinate
Oral
tamsulosin
oral
2
tamsulosin
oral
placebo
oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
solifenacin succinate
Oral
tamsulosin
oral
placebo
oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Evidence of a urinary tract infection
45 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Astellas US Medical Information
Role: STUDY_DIRECTOR
Astellas Pharma US, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Tuscon, Arizona, United States
Atherton, California, United States
Beverly Hills, California, United States
Buena, California, United States
Buena Park, California, United States
Carmichael, California, United States
Culver City, California, United States
Fresno, California, United States
Mission Hills, California, United States
Modesto, California, United States
Orange, California, United States
San Bernardino, California, United States
San Diego, California, United States
Torrance, California, United States
Aurora, Colorado, United States
Denver, Colorado, United States
Wheat Ridge, Colorado, United States
Danbury, Connecticut, United States
Clearwater, Florida, United States
Daytona Beach, Florida, United States
Fort Myers, Florida, United States
New Port Richey, Florida, United States
Orlando, Florida, United States
Orlando, Florida, United States
Pembroke Pines, Florida, United States
Pembroke Pines, Florida, United States
Tallahassee, Florida, United States
Wellington, Florida, United States
Atlanta, Georgia, United States
Blue Ridge, Georgia, United States
Marietta, Georgia, United States
Roswell, Georgia, United States
Sandy Springs, Georgia, United States
Snellville, Georgia, United States
Coeur d'Alene, Idaho, United States
Evansville, Indiana, United States
Wichita, Kansas, United States
Shreveport, Louisiana, United States
Boston, Massachusetts, United States
Watertown, Massachusetts, United States
Grand Rapids, Michigan, United States
Jackson, Mississippi, United States
West Orange, New Jersey, United States
Endwell, New York, United States
Garden City, New York, United States
New York, New York, United States
New York, New York, United States
Orchard Park, New York, United States
Poughkeepsie, New York, United States
Rochester, New York, United States
Concord, North Carolina, United States
Hickory, North Carolina, United States
Winston-Salem, North Carolina, United States
Cincinnati, Ohio, United States
Cincinnati, Ohio, United States
Bethany, Oklahoma, United States
Norman, Oklahoma, United States
Springfield, Oregon, United States
Bala-Cynwyd, Pennsylvania, United States
Bensalem, Pennsylvania, United States
Camp Hill, Pennsylvania, United States
Lancaster, Pennsylvania, United States
Uniontown, Pennsylvania, United States
Mt. Pleasant, South Carolina, United States
Simpsonville, South Carolina, United States
Nashville, Tennessee, United States
Houston, Texas, United States
Ogden, Utah, United States
Salt Lake City, Utah, United States
Virginia Beach, Virginia, United States
Mountain Lake Terrace, Washington, United States
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol. 2009 Dec;182(6):2825-30. doi: 10.1016/j.juro.2009.08.023. Epub 2009 Oct 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
905-UC-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.